carbamates has been researched along with Cognition Disorders in 34 studies
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diazepam-resistant SE was induced in adult mice fed with standard or ketogenic diet or in cannabinoid receptor type 1 (CB1) receptor knock-out mice." | 5.48 | Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet. ( Butler, CR; Guilmette, E; Pauletti, A; Piro, JR; Porcu, L; Rizzi, M; Salamone, A; Samad, TA; Sheehan, MJ; Terrone, G; Vezzani, A; Villa, BR, 2018) |
| "Recent data indicate that patients with vascular dementia (VaD) show a cholinergic deficit." | 2.71 | Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study. ( Antonello, RM; Bava, A; Cazzato, G; Griggio, S; Moretti, R; Torre, P; Ukmar, M, 2004) |
| "6 %)treatment was withdrawn because of mostly gastrointestinal adverse events." | 2.71 | Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study. ( Bardelli, F; Bencini, F; Biagini, CA; Caleri, V; Cantini, C; Cavallini, MC; Marini, M; Masotti, G; Mecacci, R; Mossello, E; Razzi, E; Sarcone, E; Tilli, S; Tonon, E, 2004) |
| " Adverse events were predominantly gastrointestinal, of mild to moderate severity, transient, and occurred mainly during escalation of the dose." | 2.69 | Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. ( Agid, Y; Anand, R; Cicin-Sain, A; Dal-Bianco, P; Gauthier, S; Gharabawi, M; Hartman, R; Rösler, M; Stähelin, HB, 1999) |
| "Therefore, additional therapies for Alzheimer's disease still need to be developed that include more tolerable agents with alternative mechanisms of action and broader efficacy." | 2.42 | Current treatments for Alzheimer's disease: cholinesterase inhibitors. ( Doody, RS, 2003) |
| " Further resarch is desirable on dosage (frequency and quanitity) in a search for ways to minimize adverse effects." | 2.41 | Rivastigmine for Alzheimer's disease. ( Birks, J; Iakovidou, V; Tsolaki, M, 2000) |
| "While insulin resistance is common in older people, large numbers also have impaired insulin secretion." | 2.40 | The elderly Type 2 diabetic patient: special considerations. ( Morley, JE, 1998) |
| "Diazepam-resistant SE was induced in adult mice fed with standard or ketogenic diet or in cannabinoid receptor type 1 (CB1) receptor knock-out mice." | 1.48 | Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet. ( Butler, CR; Guilmette, E; Pauletti, A; Piro, JR; Porcu, L; Rizzi, M; Salamone, A; Samad, TA; Sheehan, MJ; Terrone, G; Vezzani, A; Villa, BR, 2018) |
| "Treatment with donepezil and rivastigmine (successively) did not produce the desired benefits." | 1.32 | A case study in the treatment of dementia with Lewy bodies. ( Kaufer, DI, 2004) |
| "Rivastigmine (2 mg/kg) reduced cerebral edema by at least 50% (p < 0." | 1.30 | Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse. ( Chen, Y; Constantini, S; Shohami, E; Weinstock, M, 1998) |
| "Treatments in Alzheimer's disease include treatment of cognitive impairment and behavioral manifestations (agitation, depression, anxiety, delusions)." | 1.30 | [Drug therapy strategies in Alzheimer's disease]. ( Lacomblez, L, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (20.59) | 18.2507 |
| 2000's | 19 (55.88) | 29.6817 |
| 2010's | 8 (23.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Areosa Sastre, A | 1 |
| Vernooij, RW | 1 |
| González-Colaço Harmand, M | 1 |
| Martínez, G | 1 |
| Terrone, G | 1 |
| Pauletti, A | 1 |
| Salamone, A | 1 |
| Rizzi, M | 1 |
| Villa, BR | 1 |
| Porcu, L | 1 |
| Sheehan, MJ | 1 |
| Guilmette, E | 1 |
| Butler, CR | 1 |
| Piro, JR | 1 |
| Samad, TA | 1 |
| Vezzani, A | 1 |
| López-Hurtado, A | 1 |
| Burgos, DF | 1 |
| González, P | 1 |
| Dopazo, XM | 1 |
| González, V | 1 |
| Rábano, A | 1 |
| Mellström, B | 1 |
| Naranjo, JR | 1 |
| Fateev, IV | 1 |
| Subbotina, SN | 1 |
| Kurpyakova, AF | 1 |
| Tyunin, MA | 1 |
| Huber, B | 1 |
| Bocchicchio, M | 1 |
| Hasanein, P | 1 |
| Ghafari-Vahed, M | 1 |
| Meador, KJ | 1 |
| Brashear, HR | 1 |
| Wiegand, F | 1 |
| Zannikos, P | 1 |
| Novak, G | 1 |
| Mula, M | 1 |
| Dartigues, JF | 1 |
| Goulley, F | 1 |
| Bourdeix, I | 1 |
| Péré, JJ | 1 |
| Barberger-Gateau, P | 1 |
| Werber, EA | 1 |
| Gandelman-Marton, R | 1 |
| Klein, C | 1 |
| Rabey, JM | 1 |
| Doody, RS | 1 |
| Adler, G | 1 |
| Brassen, S | 1 |
| Chwalek, K | 1 |
| Dieter, B | 1 |
| Teufel, M | 1 |
| Erkinjuntti, T | 1 |
| Román, G | 1 |
| Gauthier, S | 2 |
| Feldman, H | 2 |
| Rockwood, K | 1 |
| Darreh-Shori, T | 2 |
| Hellström-Lindahl, E | 1 |
| Flores-Flores, C | 1 |
| Guan, ZZ | 1 |
| Soreq, H | 1 |
| Nordberg, A | 2 |
| Almkvist, O | 1 |
| Stefanova, E | 1 |
| Spiegel, R | 1 |
| Scheltens, P | 1 |
| Scarpini, E | 1 |
| Hermann, N | 1 |
| Mesenbrink, P | 1 |
| Mancione, L | 1 |
| Tekin, S | 1 |
| Lane, R | 1 |
| Ferris, S | 1 |
| Chez, MG | 1 |
| Aimonovitch, M | 1 |
| Buchanan, T | 1 |
| Mrazek, S | 1 |
| Tremb, RJ | 1 |
| Moretti, R | 1 |
| Torre, P | 1 |
| Antonello, RM | 1 |
| Cazzato, G | 1 |
| Griggio, S | 1 |
| Ukmar, M | 1 |
| Bava, A | 1 |
| Kaufer, DI | 1 |
| Mossello, E | 1 |
| Tonon, E | 1 |
| Caleri, V | 1 |
| Tilli, S | 1 |
| Cantini, C | 1 |
| Cavallini, MC | 1 |
| Bencini, F | 1 |
| Mecacci, R | 1 |
| Marini, M | 1 |
| Bardelli, F | 1 |
| Sarcone, E | 1 |
| Razzi, E | 1 |
| Biagini, CA | 1 |
| Masotti, G | 1 |
| Schneider, LS | 2 |
| Chen, Y | 1 |
| Shohami, E | 1 |
| Constantini, S | 1 |
| Weinstock, M | 1 |
| Meyers, CA | 1 |
| Kudelka, AP | 1 |
| Conrad, CA | 1 |
| Gelke, CK | 1 |
| Grove, W | 1 |
| Pazdur, R | 1 |
| Lacomblez, L | 1 |
| Morley, JE | 1 |
| Rösler, M | 1 |
| Anand, R | 1 |
| Cicin-Sain, A | 1 |
| Agid, Y | 1 |
| Dal-Bianco, P | 1 |
| Stähelin, HB | 1 |
| Hartman, R | 1 |
| Gharabawi, M | 1 |
| Birks, J | 2 |
| Iakovidou, V | 2 |
| Tsolaki, M | 2 |
| McKeith, IG | 2 |
| Grace, JB | 1 |
| Walker, Z | 1 |
| Byrne, EJ | 1 |
| Wilkinson, D | 1 |
| Stevens, T | 1 |
| Perry, EK | 1 |
| Reading, PJ | 1 |
| Luce, AK | 1 |
| Bottino, CM | 1 |
| Carvalho, IA | 1 |
| Alvarez, AM | 1 |
| Avila, R | 1 |
| Zukauskas, PR | 1 |
| Bustamante, SE | 1 |
| Andrade, FC | 1 |
| Hototian, SR | 1 |
| Saffi, F | 1 |
| Camargo, CH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label 24-Week, Flexible Dose Trial to Assess the Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies[NCT00230997] | Phase 3 | 50 participants | Interventional | 2002-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for carbamates and Cognition Disorders
| Article | Year |
|---|---|
Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia.
Topics: Carbamates; Cause of Death; Cognition Disorders; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypog | 2017 |
Recent and future antiepileptic drugs and their impact on cognition: what can we expect?
Topics: Acetamides; Animals; Anticonvulsants; Carbamates; Cognition; Cognition Disorders; Epilepsy; Forecast | 2012 |
Ganstigmine (CHF 2819).
Topics: Acetylcholine; Adult; Alkaloids; Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; | 2002 |
Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Topics: Alzheimer Disease; Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Clinical Trials as To | 2003 |
New therapeutic approaches to Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cognitio | 1996 |
New therapeutic approaches to cognitive impairment.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; D | 1998 |
The elderly Type 2 diabetic patient: special considerations.
Topics: Aged; Amyloid; Blood Glucose; Carbamates; Cognition Disorders; Depression; Diabetes Mellitus, Type 2 | 1998 |
Rivastigmine for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Phenylcarbama | 2000 |
Rivastigmine for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Phenylcarbama | 2000 |
12 trials available for carbamates and Cognition Disorders
| Article | Year |
|---|---|
Cognitive effects of carisbamate in randomized, placebo-controlled, healthy-volunteer, multidose studies.
Topics: Anticonvulsants; Arousal; Carbamates; Choice Behavior; Cognition Disorders; Cross-Over Studies; Dose | 2011 |
[Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorde | 2002 |
The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.
Topics: Acetylcholine; Aged; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Cognition Disorders; De | 2003 |
Prediction of treatment response to rivastigmine in Alzheimer's dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Cognition | 2004 |
Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Attention; Carbamates; Case-Control Studies; Chi-Square | 2004 |
Behavioral symptoms in mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Carbamates; Cholinesterase Inhibito | 2004 |
Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study.
Topics: Aged; Aged, 80 and over; Aspirin; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Dement | 2004 |
Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Fema | 2004 |
Neurotoxicity of CI-980, a novel mitotic inhibitor.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Cognition; Cognition Disorders; Colorectal Neoplasms | 1997 |
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase I | 1999 |
Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.
Topics: Aged; Aged, 80 and over; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Drug Tolerance; | 2000 |
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
Topics: Aged; Carbamates; Caregivers; Cognition Disorders; Female; Follow-Up Studies; Hallucinations; Humans | 2001 |
13 other studies available for carbamates and Cognition Disorders
| Article | Year |
|---|---|
Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet.
Topics: Animals; Brain; Brain Waves; Carbamates; Cognition Disorders; Diazepam; Disease Models, Animal; Dose | 2018 |
Inhibition of DREAM-ATF6 interaction delays onset of cognition deficit in a mouse model of Huntington's disease.
Topics: Activating Transcription Factor 6; Animals; Carbamates; Cognition Disorders; Disease Models, Animal; | 2018 |
Possibility of usage of aminostigmine structural analogue for the treatment of toxic cognitive disorders.
Topics: Animals; Carbamates; Cognition Disorders; Lethal Dose 50; Male; Pyridostigmine Bromide; Rats | 2014 |
A retrospective evaluation of retigabine in patients with cognitive impairment with highly drug-resistant epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamates; Cognition; Cognition Disorders; Cohort Studies; Epil | 2015 |
Fatty acid amide hydrolase inhibitor URB597 prevented tolerance and cognitive deficits induced by chronic morphine administration in rats.
Topics: Amidohydrolases; Analgesics, Opioid; Animals; Avoidance Learning; Benzamides; Carbamates; Cognition | 2016 |
Emerging therapies for vascular dementia and vascular cognitive impairment.
Topics: Carbamates; Cardiovascular Diseases; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition | 2004 |
Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.
Topics: Acetylcholinesterase; Aged; Alternative Splicing; Alzheimer Disease; Blotting, Western; Carbamates; | 2004 |
Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.
Topics: Acetylcholine; Autistic Disorder; Brain; Carbamates; Child; Child Development Disorders, Pervasive; | 2004 |
A case study in the treatment of dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Carbamates; Cognition Disorders; Donepezil; Drug Resistance; Female; Galant | 2004 |
Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse.
Topics: Animals; Brain Edema; Carbamates; Cholinergic Antagonists; Cholinesterase Inhibitors; Cognition Diso | 1998 |
[Drug therapy strategies in Alzheimer's disease].
Topics: Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Car | 1998 |
Alzheimer's disease: translating neurochemical insights into clinical benefits.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Magnetic Reso | 2000 |
[Cognitive rehabilitation in Alzheimer's disease patients: multidisciplinary team report].
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Caregivers; Chol | 2002 |